Skip to main content

Table 1 Baseline characteristics ( n = 359 )

From: Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study

Characteristic   Low dose (n = 60) Intermediate dose (n = 77) High dose (n = 222)
Gender Females 27 (45.0%) 30 (50.6%) 98 (44.1%)
  Males 33 (55.0%) 47 (49.4%) 124 (55.9%)
Age [y] Median 51.1 55.4 59.0
  Range 18.1-77.0 21.9-80.5 20.5-81.1
Disease Duration [y] Median 1.9 1.4 1.9
  Range 0.1-25.8 0.1-18.6 0.1-27.5
Pretreatment Surgery 35 (58.3%) 36 (46.8%) 125 (56.3%)
  Chemotherapy 14 (23.3%) 16 (20.8%) 38 (17.1%)
  Radiation 21 (35.0%) 31 (40.3%) 72 (32.4%)
Extent Single Metastasis 3 (5.0%) 11 (14.3%) 28 (12.6%)
  Liver Metastases 48 (80.0%) 62 (80.5%) 189 (85.1%)
  Bone Metastases 16 (26.7%) 17 (22.1%) 47 (21.2%)
Creatinine [μmol/L] Median 63 71 69
  Range 22-258 26-138 33-369
Tumor Uptake Score 1 5 (8.3%) 10 (13.0%) 18 (8.1%)
  Score 2 6 (10.0%) 8 (10.4%) 11 (5.0%)
  Score 3 49 (81.7%) 59 (76.6%) 193 (87.0%)
Kidney Uptake Score 0 2 (3.3%) 3 (3.9%) 11 (5.0%)
  Score 1 4 (6.6%) 8 (10.4%) 20 (0.2%)
  Score 2 12 (20.0%) 10 (13.0%) 52 (23.4%)
  Score 3 42 (70.0%) 55 (71.4%) 137 (61.7%)
Histology Carcinoid 19 (31.7%) 38 (49.4%) 106 (47.7%)
  PNET 15 (25.0%) 21 (17.3%) 64 (28.8%)
  Rare NET 17 (28.3%) 9 (11.7%) 26 (11.7%)
  Unknown Primary 9 (15.0%) 9 (11.7%) 26 (11.7%)
  1. PNET: pancreatic neuroendocrine tumors, NET: neuroendocrine tumors, Rare NET include: medullary thyroid cancers, neuroblastomas, phaeochromocytomas, paragangliomas, small cell lung cancers and Merkel cell cancers.